Stomach
Amylase + lipase + protease + cellulase + hyoscyamine
Digestive enzymes
Other names: Kutrase
Wait
no wait (the FAA's MedGuide)
Other FAA documents add more.
The FAA's MedGuide lists amylase + lipase + protease + cellulase + hyoscyamine (Kutrase) as allowed, for supplement, with no wait after the first dose, after later doses or after the final dose, used per label directions.
Track your medicationsCompare FAA documents: amylase + lipase + protease + cellulase + hyoscyamineWhat each of the two FAA documents says, in plain wordsOpen
Wait
- for hyoscyamine taken for colitis, the FAA's colitis worksheet says no flying for 48 hours after use
The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.
The FAA's CACI – Colitis Worksheet, for hyoscyamine taken for Crohn's disease, ulcerative colitis, microscopic colitis or irritable bowel syndrome, says use 1 to 2 times a week with no side effects and no flying for 48 hours after use; that rule is on the hyoscyamine entry.
Show the FAA's words: amylase + lipase + protease + cellulase + hyoscyamineThe official FAA wording: four passages, each with its document and dateOpen
Generic: amylase + lipase + protease + cellulase + hyoscyamine
Brand Name: Kutrase
Drug Class: Digestive enzymes
Underlying Condition: Supplement
Use: ALLOW
INITIAL Wait Time (after first dose): None
SUBSEQUENT Dose Wait Time (after each dose): None
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: Per label directions
Cause of Colitis
Crohn’s disease, ulcerative colitis, microscopic colitis, or irritable bowel syndrome
Medications for condition
One or more of the following:
hyoscyamine - use 1-2 times a week with no side effects and no-fly 48 hours after use
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.